<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CAMBIA - diclofenac potassium powder, for solution </strong><br>Nautilus Neurosciences, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use CAMBIA safely and effectively.  See full prescribing information for CAMBIA.</span><br><span class="Bold">CAMBIA (Diclofenac Potassium for Oral Solution)</span><br><span class="Bold">Initial U.S. Approval: 1988</span><br>
</div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold Underline">Cardiovascular Risk</span> </p>
<ul class="Disc">
<li>
<span class="Bold">Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Risk may increase with duration of use. (</span><a href="#H5_1">5.1</a><span class="Bold">) </span><br>
</li>
<li>
<span class="Bold">CAMBIA is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (</span><a href="#H4_0">4</a><span class="Bold">, </span><a href="#H5_1">5.1</a><span class="Bold">)</span>
</li>
</ul>
<p class="Highlighta"><span class="Bold Underline">Gastrointestinal Risk</span> </p>
<ul class="Disc"><li>
<span class="Bold">NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. Events can occur at any time without warning symptoms. Elderly patients are at greater risk. (</span><a href="#H5_2">5.2</a><span class="Bold">)</span>
</li></ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning</span></h1>
<p class="Highlighta"><span class="Bold Underline">Cardiovascular Risk</span> </p>
<ul class="Disc">
<li>
<span class="Bold">Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. Risk may increase with duration of use. (</span><a href="#H5_1">5.1</a><span class="Bold">) </span><br>
</li>
<li>
<span class="Bold">CAMBIA is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery. (</span><a href="#H4_0">4</a><span class="Bold">, </span><a href="#H5_1">5.1</a><span class="Bold">)</span>
</li>
</ul>
<p class="Highlighta"><span class="Bold Underline">Gastrointestinal Risk</span> </p>
<ul class="Disc"><li>
<span class="Bold">NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. Events can occur at any time without warning symptoms. Elderly patients are at greater risk. (</span><a href="#H5_2">5.2</a><span class="Bold">)</span>
</li></ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">CAMBIA is a non-steroidal  anti-inflammatory (NSAID) drug indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults 18 years of age or older (<a href="#H1_1">1.1</a>) </p>
<p class="Highlighta">Important Limitations (<a href="#H1_2">1.2</a>): </p>
<ul class="Disc">
<li>CAMBIA is not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span><br>
</li>
<li>Safety and effectiveness of CAMBIA not established for <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headache</span>, which is present in an older, predominantly male population</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">Single 50 mg dose; mix single packet contents with 1 to 2 ounces (30 to 60 mL) of water prior to administration (<a href="#_1__INDICATIONS">1</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Packets: Each containing buffered diclofenac potassium 50 mg in a soluble powder (<a href="#_3__DOSAGE">3</a>)  </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to diclofenac or NSAIDs (<a href="#H4_0">4</a>)<br>
</li>
<li>Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs (<a href="#H4_0">4</a>)<br>
</li>
<li>Use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery (<a href="#H4_0">4</a>, <a href="#H5_1">5.1</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and potentially fatal CV thrombotic events: Use lowest effective  dose of CAMBIA for shortest possible duration (<a href="#H5_1">5.1</a>)<br>
</li>
<li>Serious and potentially fatal GI reactions: Use lowest effective dose of CAMBIA for shortest possible duration; use with caution in patients with prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#H5_2">5.2</a>)<br>
</li>
<li>Hepatic effects: Range from transaminase elevations to <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>;  discontinue CAMBIA immediately if abnormal liver tests persist or worsen (<a href="#H5_3">5.3</a>, <a href="#H5_13">5.13</a>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>: Can occur with NSAID treatment. Monitor blood pressure closely during treatment with CAMBIA (<a href="#H5_4">5.4</a>) <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> can occur with NSAID treatment; use CAMBIA with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#H5_5">5.5</a>)<br>
</li>
<li>Renal effects: Long-term administration of NSAIDs can result in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>; use CAMBIA with caution in patients at risk (e.g., the elderly, those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver impairment, and those taking diuretics or ACE inhibitors) (<a href="#H5_6">5.6</a>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span>: May occur in patients with the aspirin triad or in patients without prior exposure to CAMBIA; discontinue CAMBIA immediately if an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> occurs (<a href="#H5_7">5.7</a>)<br>
</li>
<li>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>: Include <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, which can be fatal; discontinue CAMBIA if <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or other signs of local <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reaction</span> occur (<a href="#H5_8">5.8</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥1% and &gt;placebo) were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and dizziness (<a href="#H6_1">6.1</a>)<br> </p>
<p class="Highlighta"><span class="Bold"><br><br>To report SUSPECTED ADVERSE REACTIONS contact Nautilus Neurosciences, Inc. at 877-874-2440 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Aspirin: Concomitant administration with other NSAIDs, including aspirin,  is not recommended because of an increased risk of adverse reactions, including GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#H7_1">7.1</a>)<br>
</li>
<li>Anticoagulants: Concomitant use of diclofenac and anticoagulants (e.g., warfarin) increases the risk of serious GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#H7_2">7.2</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pregnancy: Based on animal data, may cause fetal harm. Based on human data, starting at 30 weeks gestation, CAMBIA should be avoided as premature closure of the ductus arteriosus in the fetus may occur (<a href="#H5_9">5.9</a>, <a href="#H8_1">8.1</a>)<br>
</li>
<li>Nursing Mothers: Use with caution, as it is not known if diclofenac is excreted in human milk (<a href="#H8_3">8.3</a>)<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic insufficiency</span>: The liver metabolizes almost 100% of diclofenac; there is insufficient information available to support dosing recommendations for CAMBIA in patients with hepatic insufficiency  (<a href="#H5_3">5.3</a>, <a href="#H8_6">8.6</a>, <a href="#H12_3">12.3</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 4/2010</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></a></h1>
<h1><a href="#section-1" class="toc"><span class="Bold">1 </span><span class="Bold">
		     
	INDICATIONS AND USAGE</span></a></h1>
<h2><a href="#section-1.1" class="toc"><span class="Bold">1.1</span><span class="Bold"> Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> </span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="Bold">1.2</span><span class="Bold"> Important Limitations </span></a></h2>
<h1><a href="#section-2" class="toc"><span class="Bold">2</span><span class="Bold"> </span><span class="Bold">
		     
	DOSAGE AND ADMINISTRATION</span>
		     
	</a></h1>
<h2><a href="#section-2.1" class="toc"><span class="Bold">2.1</span><span class="Bold"> Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="Bold">2.2</span><span class="Bold"> Interchangeability With Other Formulations of Diclofenac</span></a></h2>
<h1><a href="#section-3" class="toc"><span class="Bold">3 </span><span class="Bold">
		     
	DOSAGE FORMS AND STRENGTHS</span></a></h1>
<h1><a href="#section-4" class="toc"><span class="Bold">4</span><span class="Bold"> </span><span class="Bold">
		     
	CONTRAINDICATIONS</span></a></h1>
<h1><a href="#section-5" class="toc"><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">
		     
	WARNINGS AND PRECAUTIONS</span></a></h1>
<h2><a href="#section-5.1" class="toc"><span class="Bold">5.1</span><span class="Bold"> Cardiovascular Thrombotic Events</span></a></h2>
<h2><a href="#section-5.2" class="toc"><span class="Bold">5.2</span><span class="Bold"> Gastrointestinal Effects  - Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="Bold">5.3</span><span class="Bold"> Hepatic Effects</span></a></h2>
<h2><a href="#section-5.4" class="toc"><span class="Bold">5.4</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></a></h2>
<h2><a href="#section-5.5" class="toc"><span class="Bold">5.5</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </span></a></h2>
<h2><a href="#section-5.6" class="toc"><span class="Bold">5.</span><span class="Bold">6</span><span class="Bold"> Renal Effects </span></a></h2>
<h2><a href="#section-5.7" class="toc"><span class="Bold">5.</span><span class="Bold">7</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></a></h2>
<h2><a href="#section-5.8" class="toc"><span class="Bold">5.</span><span class="Bold">8</span><span class="Bold"> Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span></a></h2>
<h2><a href="#section-5.9" class="toc"><span class="Bold">5.9</span><span class="Bold"> Pregnancy</span></a></h2>
<h2><a href="#section-5.10" class="toc"><span class="Bold">5.1</span><span class="Bold">0</span><span class="Bold"> Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></a></h2>
<h2><a href="#section-5.11" class="toc"><span class="Bold">5.</span><span class="Bold">1</span><span class="Bold">1</span><span class="Bold"> Hematologic Effects </span></a></h2>
<h2><a href="#section-5.12" class="toc"><span class="Bold">5.</span><span class="Bold">1</span><span class="Bold">2</span><span class="Bold"> Use in Patients With Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> </span></a></h2>
<h2><a href="#section-5.13" class="toc"><span class="Bold">5.</span><span class="Bold">1</span><span class="Bold">3</span><span class="Bold"> Monitoring</span></a></h2>
<h2><a href="#section-5.14" class="toc"><span class="Bold">5.1</span><span class="Bold">4</span><span class="Bold"> Phenylketonurics</span></a></h2>
<h1><a href="#section-6" class="toc"><span class="Bold">6</span><span class="Bold"> </span>
		     
	<span class="Bold">ADVERSE REACTIONS </span></a></h1>
<h2><a href="#section-6.1" class="toc"><span class="Bold">6.1</span><span class="Bold"> Clinical Studies Experience With CAMBIA</span></a></h2>
<h2><a href="#section-6.2" class="toc"><span class="Bold">6.2</span><span class="Bold"> </span><span class="Bold">Adverse Reactions Reported With Diclofenac and Other NSAIDs</span></a></h2>
<h1><a href="#section-7" class="toc"><span class="Bold">7</span><span class="Bold"> </span>
		     
	<span class="Bold">DRUG INTERACTIONS</span></a></h1>
<h2><a href="#section-7.1" class="toc"><span class="Bold">7.1</span><span class="Bold"> </span><span class="Bold">Aspirin </span></a></h2>
<h2><a href="#section-7.2" class="toc"><span class="Bold">7.2</span><span class="Bold"> Anticoagulants</span></a></h2>
<h2><a href="#section-7.3" class="toc"><span class="Bold">7.</span><span class="Bold">3</span><span class="Bold"> ACE Inhibitors </span></a></h2>
<h2><a href="#section-7.4" class="toc"><span class="Bold">7.</span><span class="Bold">4</span><span class="Bold"> Diuretics </span></a></h2>
<h2><a href="#section-7.5" class="toc"><span class="Bold">7.</span><span class="Bold">5</span><span class="Bold"> Lithium </span></a></h2>
<h2><a href="#section-7.6" class="toc"><span class="Bold">7.</span><span class="Bold">6</span><span class="Bold"> Methotrexate </span></a></h2>
<h2><a href="#section-7.7" class="toc"><span class="Bold">7.</span><span class="Bold">7</span><span class="Bold"> Cyclosporine </span></a></h2>
<h2><a href="#section-7.8" class="toc"><span class="Bold">7.8</span><span class="Bold"> Inhibitors of Cytochrome P450 2C9</span></a></h2>
<h1><a href="#section-8" class="toc"><span class="Bold">8</span><span class="Bold"> </span>
		     
	<span class="Bold">USE IN SPECIFIC POPULATIONS</span>
		     
	</a></h1>
<h2><a href="#section-8.1" class="toc"><span class="Bold">8.1</span><span class="Bold"> Pregnancy </span></a></h2>
<h2><a href="#section-8.2" class="toc"><span class="Bold">8.2</span><span class="Bold"> Labor and Delivery</span><span class="Bold"> </span></a></h2>
<h2><a href="#section-8.3" class="toc"><span class="Bold">8.</span><span class="Bold">3</span><span class="Bold"> </span><span class="Bold">Nursing Mothers</span></a></h2>
<h2><a href="#section-8.4" class="toc"><span class="Bold">8.</span><span class="Bold">4</span><span class="Bold"> Pediatric Use</span></a></h2>
<h2><a href="#section-8.5" class="toc"><span class="Bold">8.</span><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">Geriatric Use</span></a></h2>
<h2><a href="#section-8.6" class="toc"><span class="Bold">8.6</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></a></h2>
<h2><a href="#section-8.7" class="toc"><span class="Bold">8.7 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></a></h2>
<h1><a href="#section-9" class="toc"><span class="Bold">10</span><span class="Bold"> </span>
		     
	<span class="Bold">OVERDOSAGE</span></a></h1>
<h1><a href="#section-10" class="toc"><span class="Bold">11</span><span class="Bold"> </span>
		     
	<span class="Bold">DESCRIPTION</span></a></h1>
<h1><a href="#section-11" class="toc"><span class="Bold">12</span><span class="Bold"> </span>
		     
	<span class="Bold">CLINICAL PHARMACOLOGY</span></a></h1>
<h2><a href="#section-11.1" class="toc"><span class="Bold">12.1</span><span class="Bold">  Mechanism of Action</span></a></h2>
<h2><a href="#section-11.2" class="toc"><span class="Bold">12.3</span><span class="Bold">  Pharmacokinetics</span></a></h2>
<h1><a href="#section-12" class="toc"><span class="Bold">13</span><span class="Bold"> </span>
		     
	<span class="Bold">NON-CLINICAL STUDIES  </span></a></h1>
<h2><a href="#section-12.1" class="toc"><span class="Bold">13.1</span><span class="Bold"> Carcinogenesis, Mutagenesis, Impairment of Fertility</span></a></h2>
<h1><a href="#section-13" class="toc"><span class="Bold">14</span><span class="Bold"> </span>
		     
	<span class="Bold">CLINICAL STUDIES </span></a></h1>
<h1><a href="#section-14" class="toc"><span class="Bold">16</span><span class="Bold"> </span>
		     
	<span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span></a></h1>
<h1><a href="#section-15" class="toc"><span class="Bold">17  PATIENT COUNSELING INFORMATION</span></a></h1>
<h2><a href="#section-15.1" class="toc"><span class="Bold">17.1</span><span class="Bold"> Cardiovascular Effects </span></a></h2>
<h2><a href="#section-15.2" class="toc"><span class="Bold">17.</span><span class="Bold">2</span><span class="Bold"> Gastrointestinal Effects</span></a></h2>
<h2><a href="#section-15.3" class="toc"><span class="Bold">17.</span><span class="Bold">3</span><span class="Bold"> Hepatotoxicity</span></a></h2>
<h2><a href="#section-15.4" class="toc"><span class="Bold">17.4</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span></a></h2>
<h2><a href="#section-15.5" class="toc"><span class="Bold">17.5</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span></a></h2>
<h2><a href="#section-15.6" class="toc"><span class="Bold">17.</span><span class="Bold">6</span><span class="Bold"> Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span></a></h2>
<h2><a href="#section-15.7" class="toc"><span class="Bold">17.</span><span class="Bold">7</span><span class="Bold"> Effects During Pregnancy</span></a></h2>
<h2><a href="#section-15.8" class="toc"><span class="Bold">17.8</span><span class="Bold"> Phenylketonurics</span></a></h2>
<h2><a href="#section-15.9" class="toc"><span class="Bold">17.9</span><span class="Bold"> </span><span class="Bold">FDA-Approved Medication Guide </span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS</span></h1>
<p class="First"><span class="Bold Underline">Cardiovascular Risk</span></p>
<p><span class="Bold">Non-steroidal anti-inflammatory drugs (NSAIDs) may increase the risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk [</span><span class="Bold Italics">see Warnings and Precautions </span><span class="Bold Italics">(</span><span class="Italics"><a href="#H5_1">5.1</a></span><span class="Bold Italics">)</span><span class="Bold Italics">].</span></p>
<p><span class="Bold">CAMBIA is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery [see Contraindications </span><span class="Bold Italics">(</span><span class="Italics"><a href="#H4_0">4</a></span><span class="Bold Italics">) and </span><span class="Bold Italics">Warnings and Precautions (</span><span class="Italics"><a href="#H5_1">5.1</a></span><span class="Bold Italics">)</span><span class="Bold Italics">]</span><span class="Bold">.</span></p>
<p><span class="Bold Underline">Gastrointestinal Risk</span></p>
<p><span class="Bold">NSAIDs increase the risk of serious gastrointestinal (GI) adverse events including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events [</span><span class="Bold Italics">see Warnings and Precautions </span><span class="Bold Italics">(</span><span class="Italics"><a href="#H5_2">5.2</a></span><span class="Bold Italics">)</span><span class="Bold Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="_1__INDICATIONS"></a><a name="section-1"></a><p></p>
<h1>
<span class="Bold">1 </span><span class="Bold">
		     
	INDICATIONS AND USAGE</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="H1_1"></a><a name="section-1.1"></a><p></p>
<h2>
<span class="Bold">1.1</span><span class="Bold"> Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> </span>
</h2>
<p class="First">
		     
	CAMBIA<span class="Bold">™</span> (Diclofenac Potassium for Oral Solution)<span class="Bold"> </span>is indicated for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span> in adults (18 years of age or older).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H1_2"></a><a name="section-1.2"></a><p></p>
<h2>
<span class="Bold">1.2</span><span class="Bold"> Important Limitations </span>
</h2>
<ul class="Disc">
<li>CAMBIA is not indicated for the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.<br>
</li>
<li>The safety and effectiveness of CAMBIA have not been established for cluster <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, which is present in an older, predominantly male population.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>
<span class="Bold">2</span><span class="Bold"> </span><span class="Bold">
		     
	DOSAGE AND ADMINISTRATION</span>
		     
	</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="H2_1"></a><a name="section-2.1"></a><p></p>
<h2>
<span class="Bold">2.1</span><span class="Bold"> Acute Treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></span>
</h2>
<p class="First">
		     
	Administer one packet (50 mg) of CAMBIA<span class="Bold">™</span><span class="Bold"> </span> for the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>.  Empty the contents of one packet into a cup containing 1 to 2 ounces (30 to 60 mL) of water, mix well and drink immediately. Do not use liquids other than water.</p>
<p>
		     
	Taking CAMBIA with food may cause a reduction in effectiveness compared to taking CAMBIA on an empty stomach <span class="Italics">[see Clinical Pharmacology (</span><span class="Italics"><a href="#H12_3">12.3</a></span><span class="Italics">)]</span>. </p>
<p>
		     
	Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals.  The safety and effectiveness of a second dose have not been established.  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H2_2"></a><a name="section-2.2"></a><p></p>
<h2>
<span class="Bold">2.2</span><span class="Bold"> Interchangeability With Other Formulations of Diclofenac</span>
</h2>
<p class="First">
		     
	Different formulations of oral diclofenac (e.g., CAMBIA, diclofenac sodium enteric-coated tablets, diclofenac sodium extended-release tablets, or diclofenac potassium immediate-release tablets) may not be bioequivalent even if the milligram strength is the same. Therefore, it is not possible to convert dosing from any other formulation of diclofenac to CAMBIA.</p>
<p>
		     
	</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="_3__DOSAGE"></a><a name="section-3"></a><p></p>
<h1>
<span class="Bold">3 </span><span class="Bold">
		     
	DOSAGE FORMS AND STRENGTHS</span>
</h1>
<p class="First">
		     
	CAMBIA<span class="Bold"> </span>  is available in individual packets each designed to deliver a 50 mg dose when mixed in water. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="H4_0"></a><a name="section-4"></a><p></p>
<h1>
<span class="Bold">4</span><span class="Bold"> </span><span class="Bold">
		     
	CONTRAINDICATIONS</span>
</h1>
<ul class="Disc">
<li>CAMBIA is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (e.g., <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> and serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>) to diclofenac <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_7">5.7</a></span><span class="Italics">, </span><span class="Italics"><a href="#H5_8">5.8</a></span><span class="Italics">)]</span>. <br>
</li>
<li>CAMBIA is contraindicated in patients who have experienced <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, or allergic-type reactions after taking aspirin or other NSAIDs.  Severe, sometimes fatal, anaphylactic-like reactions to NSAIDs have been reported in such patients <span class="Italics">[see Warnings and Precautions (</span><a href="#H5_7">5.7</a><span class="Italics">, </span><span class="Italics"><a href="#H5_12">5.12</a></span><span class="Italics">)]</span>.<br>
</li>
<li>CAMBIA is contraindicated for the treatment of peri-operative <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the setting of coronary artery bypass graft (CABG) surgery <span class="Italics">[see Warnings and Precautions (</span><a href="#H5_1">5.1</a><span class="Italics">)]</span>.  </li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="H5_0"></a><a name="section-5"></a><p></p>
<h1>
<span class="Bold">5</span><span class="Bold"> </span><span class="Bold">
		     
	WARNINGS AND PRECAUTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_1"></a><a name="section-5.1"></a><p></p>
<h2>
<span class="Bold">5.1</span><span class="Bold"> Cardiovascular Thrombotic Events</span>
</h2>
<p class="First">
		     
	Clinical trials of several COX-2 selective and nonselective NSAIDs of up to three years’ duration have shown an increased risk of serious cardiovascular (CV) thrombotic events, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which can be fatal. All NSAIDs, both COX-2 selective and nonselective, may have a similar risk. Patients with known CV disease or risk factors for CV disease may be at greater risk. To minimize the potential risk for an adverse CV event in patients treated with an NSAID, use the lowest effective dose for the shortest duration possible.  Physicians and patients should remain alert for the development of such events, even in the absence of previous CV symptoms. Inform patients about the signs and symptoms of serious CV events and the steps to take if they occur.</p>
<p>
		     
	There is no consistent evidence that concurrent use of aspirin mitigates the increased risk of serious CV thrombotic events associated with NSAID use. The concurrent use of aspirin and an NSAID increases the risk of serious GI events <span class="Italics">[see </span><span class="Italics">Warnings and Precautions</span><span class="Italics"> (</span><span class="Italics"><a href="#H5_2">5.2</a></span><span class="Italics">)]</span>.</p>
<p>
		     
	Two large, controlled, clinical trials of a COX-2 selective NSAID for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in the first 10-14 days following coronary artery bypass graft (CABG) surgery found an increased incidence of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="Italics">[see </span><span class="Italics">Contraindications</span><span class="Italics"> (</span><span class="Italics"><a href="#H4_0">4</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
<p>
		     
	 </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_2"></a><a name="section-5.2"></a><p></p>
<h2>
<span class="Bold">5.2</span><span class="Bold"> Gastrointestinal Effects  - Risk of Ulceration, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and Perforation </span>
</h2>
<p class="First">
		     
	NSAIDs, including CAMBIA, can cause serious gastrointestinal (GI) adverse events such as <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, ulceration, and perforation of the stomach, small intestine or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with NSAIDs. Only one in five patients who develop a serious upper GI adverse event on NSAID therapy is symptomatic. Upper GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or perforation caused by NSAIDs occur in approximately 1% of patients treated for 3-6 months, and in about 2%-4% of patients treated for one year.  These trends continue with longer duration of use, thus increasing the likelihood of developing a serious GI event at some time during the course of therapy.  However, even short-term NSAID therapy is not without risk. </p>
<p>
		     
	Prescribe NSAIDs, including CAMBIA, with extreme caution in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> disease or GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients with a prior history of <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span> and/or <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span><span class="Italics"> </span>who use NSAIDs have a greater than 10-fold risk for developing a <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> than patients with neither of these risk factors.   Other factors that increase the risk for GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status.  Most spontaneous reports of fatal GI events are in elderly or debilitated patients, and therefore special care should be taken in treating this population.  </p>
<p>
		     
	To minimize the potential risk for an adverse GI event in patients treated with an NSAID, use the lowest effective dose for the shortest possible duration. Patients and physicians should remain alert for signs and symptoms of GI ulceration and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during CAMBIA therapy and promptly initiate additional evaluation and treatment if a serious GI adverse event is suspected.  This should include discontinuation of the CAMBIA until a serious GI adverse event is ruled out.  For high risk patients, alternative therapies that do not include NSAIDs should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_3"></a><a name="section-5.3"></a><p></p>
<h2>
<span class="Bold">5.3</span><span class="Bold"> Hepatic Effects</span>
</h2>
<p class="First">
		     
	Elevations of one or more liver tests may occur during therapy with CAMBIA. These laboratory abnormalities may progress, may persist, or may only be transient with continued therapy. Borderline elevations (less than 3 times the upper limit of the normal [ULN] range) or greater elevations of transaminases occurred in about 15% of diclofenac-treated patients. Of the markers of hepatic function, ALT (SGPT) is recommended for the monitoring of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.</p>
<p>
		     
	In clinical trials, meaningful elevations (i.e., more than 3 times the ULN) of AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) occurred in about 2% of approximately 5,700 patients at some time during treatment (ALT was not measured in all studies). In an open-label, controlled trial of 3,700 patients treated for 2–6 months, patients were monitored at 8 weeks and 1,200 patients were monitored again at 24 weeks.  Meaningful elevations of ALT and/or AST occurred in about 4% of the 3,700 patients and included marked elevations (&gt;8 times the ULN) in about 1% of the 3,700 patients. In this open-label study, a higher incidence of borderline (less than 3 times the ULN), moderate (3–8 times the ULN), and marked (&gt;8 times the ULN) elevations of ALT or AST was observed in patients receiving diclofenac when compared to other NSAIDs..  Almost all meaningful elevations in transaminases were detected before patients became symptomatic. </p>
<p>
		     
	Abnormal tests occurred during the first 2 months of therapy with diclofenac in 42 of the 51 patients in all trials who developed marked transaminase elevations.  In postmarketing reports, cases of drug-induced hepatotoxicity have been reported in the first month, and in some cases, the first 2 months of NSAID therapy, but can occur at any time during treatment with diclofenac. </p>
<p>
		     
	Postmarketing surveillance has reported cases of severe hepatic reactions, including <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> with and without <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, and <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>. Some of these reported cases resulted in fatalities or liver transplantation.</p>
<p>
		     
	
		     
	Measure transaminases (ALT and AST) periodically in patients receiving long-term therapy with diclofenac because severe hepatotoxicity may develop without a prodrome of distinguishing symptoms. The optimum times for making the first and subsequent transaminase measurements are not known. Based on clinical trial data and postmarketing experiences, transaminases should be monitored within 4 to 8 weeks after initiating treatment with diclofenac. However, severe hepatic reactions can occur at any time during treatment with diclofenac.  If abnormal liver tests persist or worsen, if clinical signs and/or symptoms consistent with liver disease develop, or if systemic manifestations occur (e.g., <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, dark urine, etc.), discontinue CAMBIA immediately.</p>
<p>
		     
	To minimize the possibility that hepatic injury will become severe between transaminase measurements, inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and "flu-like" symptoms), and the appropriate action patients should take if these signs and symptoms appear.</p>
<p>
		     
	To minimize the potential risk for an adverse liver-related event in patients treated with CAMBIA, use the lowest effective dose for the shortest duration possible. Exercise caution when prescribing CAMBIA with concomitant drugs that are known to be potentially hepatotoxic (e.g., acetaminophen, certain antibiotics, antiepileptics). Caution patients to avoid taking nonprescription acetaminophen-containing products while using CAMBIA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_4"></a><a name="section-5.4"></a><p></p>
<h2>
<span class="Bold">5.4</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span>
</h2>
<p class="First">
		     
	NSAIDs, including CAMBIA, can lead to new onset or worsening of pre-existing <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, either of which may contribute to the increased incidence of CV events. Use NSAIDs, including CAMBIA, with caution in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Monitor blood pressure closely during the initiation of NSAID treatment and throughout the course of therapy.</p>
<p>
		     
	Patients taking ACE inhibitors, thiazides, or loop diuretics may have impaired response to these therapies when taking NSAIDs. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_5"></a><a name="section-5.5"></a><p></p>
<h2>
<span class="Bold">5.5</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> </span>
</h2>
<p class="First">
		     
	<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been observed in some patients taking NSAIDs. Use CAMBIA with caution in patients with <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_6"></a><a name="section-5.6"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">6</span><span class="Bold"> Renal Effects </span>
</h2>
<p class="First">
		     
	Use caution when initiating treatment with CAMBIA in patients with considerable <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>. </p>
<p>
		     
	Long-term administration of NSAIDs has resulted in <span class="product-label-link" type="condition" conceptid="4152839" conceptname="Acute papillary necrosis">renal papillary necrosis</span> and other <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, liver dysfunction, those taking diuretics or ACE inhibitors, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state. </p>
<p>
		     
	No information is available from controlled clinical studies regarding the use of CAMBIA in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with CAMBIA is not recommended in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.  If CAMBIA therapy must be initiated, close monitoring of the patient's renal function is advisable.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_7"></a><a name="section-5.7"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">7</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span>
</h2>
<p class="First">
		     
	As with other NSAIDs, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> may occur in patients without known prior exposure to CAMBIA. CAMBIA is contraindicated in patients with the aspirin triad. This symptom complex typically occurs in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> patients who experience <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="253788" conceptname="Nasal polyp">nasal polyps</span>, or who exhibit severe, potentially fatal <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> after taking aspirin or other NSAIDs. <span class="Italics">[</span><span class="Italics">see </span><span class="Italics">Contraindications (</span><span class="Italics"><a href="#H4_0">4</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_8"></a><a name="section-5.8"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">8</span><span class="Bold"> Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span>
</h2>
<p class="First">
		     
	NSAIDs, including CAMBIA, can cause serious skin adverse reactions such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal.  These serious events may occur without warning. Inform patients about the signs and symptoms of serious skin manifestations and to discontinue CAMBIA at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="H5_9"></a><a name="section-5.9"></a><p></p>
<h2>
<span class="Bold">5.9</span><span class="Bold"> Pregnancy</span>
</h2>
<p class="First">
		     
	CAMBIA can cause fetal harm when administered to a pregnant woman. Starting at 30 weeks gestation, CAMBIA and other NSAIDs should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur. If this drug is used during this time period in pregnancy, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[s</span><span class="Italics">ee Use in Special Populations (</span><a href="#H8_1">8.1</a><span class="Italics">)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_10"></a><a name="section-5.10"></a><p></p>
<h2>
<span class="Bold">5.1</span><span class="Bold">0</span><span class="Bold"> Masking of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span>
</h2>
<p class="First">
		     
	The pharmacological activity of NSAIDs in reducing <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> and possibly <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> may diminish the utility of these diagnostic signs in detecting complications of presumed noninfectious, painful conditions. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_11"></a><a name="section-5.11"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">1</span><span class="Bold">1</span><span class="Bold"> Hematologic Effects </span>
</h2>
<p class="First">
		     
	<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> may occur in patients receiving NSAIDs.  This may be due to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, occult or gross GI blood loss, or an incompletely described effect upon erythropoiesis. In patients on long-term therapy with NSAIDs, including CAMBIA, check hemoglobin or hematocrit if they exhibit any signs or symptoms of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> or blood loss. </p>
<p>
		     
	NSAIDs inhibit platelet aggregation and have been shown to prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> in some patients. Unlike aspirin, the NSAID effect on platelet function is quantitatively less, of shorter duration, and reversible.  Carefully monitor patients treated with CAMBIA who may be adversely affected by alterations in platelet function, such as those with <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">coagulation disorders</span> or patients receiving anticoagulants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_12"></a><a name="section-5.12"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">1</span><span class="Bold">2</span><span class="Bold"> Use in Patients With Pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> </span>
</h2>
<p class="First">
		     
	Patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> may have aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. The use of aspirin in patients with aspirin-sensitive <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> has been associated with severe <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> which can be fatal. Since cross-reactivity, including <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, between aspirin and other NSAIDs has been reported in such aspirin-sensitive patients, CAMBIA is contraindicated in patients with this form of aspirin sensitivity and should be used with caution in all patients with pre-existing <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_13"></a><a name="section-5.13"></a><p></p>
<h2>
<span class="Bold">5.</span><span class="Bold">1</span><span class="Bold">3</span><span class="Bold"> Monitoring</span>
</h2>
<p class="First">
		     
	Because serious GI ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, physicians should monitor for signs or symptoms of GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. </p>
<p>
		     
	For patients on long-term treatment with NSAIDs, including CAMBIA, periodically perform a CBC and chemistry profile. Discontinue CAMBIA if abnormal liver tests or renal tests persist or worsen.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H5_14"></a><a name="section-5.14"></a><p></p>
<h2>
<span class="Bold">5.1</span><span class="Bold">4</span><span class="Bold"> Phenylketonurics</span>
</h2>
<p class="First">
		     
	CAMBIA contains aspartame equivalent to phenylalanine 25 mg per packet.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="H6_0"></a><a name="section-6"></a><p></p>
<h1>
<span class="Bold">6</span><span class="Bold"> </span>
		     
	<span class="Bold">ADVERSE REACTIONS </span>
</h1>
<p class="First">
		     
	The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<ul>
<li>Cardiovascular thrombotic events <span class="Italics">[see Boxed Warning and Warnings and Precautions (</span><span class="Italics"><a href="#H5_1">5.1</a></span><span class="Italics">)]</span><br>
</li>
<li>Gastrointestinal effects <span class="Italics">[see Boxed Warning and Warnings and Precautions (</span><span class="Italics"><a href="#H5_2">5.2</a></span><span class="Italics">)]</span><br>
</li>
<li>Hepatic effects <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_3">5.3</a></span><span class="Italics">)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_4">5.4</a></span><span class="Italics">)]</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span><span class="Italics"> </span><span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_5">5.5</a></span><span class="Italics">)]</span><br>
</li>
<li>Renal Effects  <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_6">5.6</a></span><span class="Italics">)]</span><br>
</li>
<li>Anaphylactoid Reactions <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_7">5.7</a></span><span class="Italics">)]</span><br>
</li>
<li>Serious Skin Reactions <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_8">5.8</a></span><span class="Italics">)]</span>
</li>
</ul>
<p>
		     
	The most common adverse reactions reported with CAMBIA<span class="Bold"> </span>are <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. </p>
<p>
		     
	The most common adverse events resulting in discontinuation of patients following CAMBIA dosing in controlled clinical trials were <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> (0.2%) and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> (0.2%). </p>
<div class="Section" data-sectionCode="42229-5">
<a name="H6_1"></a><a name="section-6.1"></a><p></p>
<h2>
<span class="Bold">6.1</span><span class="Bold"> Clinical Studies Experience With CAMBIA</span>
</h2>
<p class="First">
		     
	Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>
		     
	The safety of a single dose of CAMBIA was evaluated in 2 placebo-controlled trials with a total of 634 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> patients treated with CAMBIA for a single <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. Following treatment with diclofenac potassium (either CAMBIA or diclofenac potassium immediate-release tablets [as a control]), 5 subjects (0.8%) withdrew from the studies; following placebo exposure, 1 subject (0.2%) withdrew.  No withdrawals were due to a serious reaction.  </p>
<p>
		     
	The most common adverse reactions (i.e., that occurred in 1% or more of CAMBIA-treated patients) and more frequent with CAMBIA than with placebo were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (see <a href="#T1">Table 1</a>).</p>
<a name="iccd40296-5a94-453d-8b71-49e46d923a97"></a><table>
<caption><span>Table 1: Treatment-Related Adverse Reactions With Incidence &gt;1% and Greater Than Placebo in Studies 1 and 2 Combined</span></caption>
<col width="156">
<col width="60">
<col width="94">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule">
<span class="Bold Underline">Disorder</span><br>
		     
	Event</td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold">CAMBIA</span><br>N=634</td>
<td class="Lrule Rrule Toprule" align="center">
<span class="Bold">Placebo</span><br>N=646</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold Underline">Gastrointestinal</span><br>
		     
	<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Lrule Rrule Toprule" align="center">
<br>3%</td>
<td class="Lrule Rrule Toprule" align="center">
<br>2%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">
<span class="Bold Underline">Nervous System</span><br>
		     
	<span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule Rrule Toprule" align="center">
<br>1%</td>
<td class="Lrule Rrule Toprule" align="center">
<br>0.5%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H6_2"></a><a name="section-6.2"></a><p></p>
<h2>
<span class="Bold">6.2</span><span class="Bold"> </span><span class="Bold">Adverse Reactions Reported With Diclofenac and Other NSAIDs</span>
</h2>
<p class="First">
		     
	In patients taking diclofenac or other NSAIDs, the most frequently reported adverse reactions occurring in approximately 1%-10% of patients are: </p>
<p>GI reactions (including <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gross <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>/perforation, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, GI <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> [gastric/duodenal], and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>), abnormal renal function, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, elevated liver enzymes, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>, and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>. </p>
<p>
		     
	</p>
<p>
		     
	Additional adverse reactions reported in patients taking  NSAIDs include occasionally: </p>
<p><span class="Underline">Body as a Whole</span>:   <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> </p>
<p><span class="Underline">Cardiovascular System</span>:   <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> </p>
<p><span class="Underline">Digestive System</span>:   <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, gastric/<span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcers</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> </p>
<p><span class="Underline">Hemic and Lymphatic System</span>:  <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> </p>
<p><span class="Underline">Metabolic and Nutritional</span>:   Weight changes </p>
<p><span class="Underline">Nervous System</span>:   <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, dream abnormalities, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> </p>
<p><span class="Underline">Respiratory System</span>:   <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> </p>
<p><span class="Underline">Skin and Appendages</span>:   <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span> </p>
<p><span class="Underline">Special Senses</span>:   <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> </p>
<p><span class="Underline">Urogenital System</span>:   <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span>, <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>/<span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> </p>
<p>
		     
	</p>
<p>
		     
	Other adverse reactions in patients taking  NSAIDs, which occur rarely , are: </p>
<p><span class="Underline">Body as a Whole</span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span>, appetite changes, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> </p>
<p><span class="Underline">Cardiovascular System</span>: <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span> </p>
<p><span class="Underline">Digestive System</span>: <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">Colitis</span>, <span class="product-label-link" type="condition" conceptid="4152350" conceptname="Burping">eructation</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span> </p>
<p><span class="Underline">Hemic and Lymphatic System</span>: <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span> </p>
<p><span class="Underline">Metabolic and Nutritional</span>: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> </p>
<p><span class="Underline">Nervous System</span>: <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> </p>
<p><span class="Underline">Respiratory System</span>: <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> </p>
<p><span class="Underline">Skin and Appendages</span>: <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> </p>
<p><span class="Underline">Special Senses</span>: <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span>, hearing impairment </p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="H7_0"></a><a name="section-7"></a><p></p>
<h1>
<span class="Bold">7</span><span class="Bold"> </span>
		     
	<span class="Bold">DRUG INTERACTIONS</span>
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_1"></a><a name="section-7.1"></a><p></p>
<h2>
<span class="Bold">7.1</span><span class="Bold"> </span><span class="Bold">Aspirin </span>
</h2>
<p class="First">
		     
	When administered with aspirin, diclofenac potassium’s protein binding is reduced.  The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of CAMBIA<span class="Bold"> </span>and aspirin is not generally recommended because of the potential of increased adverse effects. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_2"></a><a name="section-7.2"></a><p></p>
<h2>
<span class="Bold">7.2</span><span class="Bold"> Anticoagulants</span>
</h2>
<p class="First">
		     
	The effects of anticoagulants such as warfarin and NSAIDs on GI <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that with use of either drug alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_3"></a><a name="section-7.3"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">3</span><span class="Bold"> ACE Inhibitors </span>
</h2>
<p class="First">
		     
	NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking CAMBIA concomitantly with ACE inhibitors. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_4"></a><a name="section-7.4"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">4</span><span class="Bold"> Diuretics </span>
</h2>
<p class="First">
		     
	Clinical studies, as well as post-marketing observations, have shown that diclofenac potassium can reduce the natriuretic effect of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, observe patients closely for signs of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> as well as to assure diuretic efficacy <span class="Italics">[see </span><span class="Italics">Warnings and Preca</span><span class="Italics">utions (</span><a href="#H5_6">5.6</a><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_5"></a><a name="section-7.5"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">5</span><span class="Bold"> Lithium </span>
</h2>
<p class="First">
		     
	NSAIDs have produced elevations of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID.  When CAMBIA and lithium are administered concurrently, observe patients carefully for signs of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_6"></a><a name="section-7.6"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">6</span><span class="Bold"> Methotrexate </span>
</h2>
<p class="First">
		     
	NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. This indicates that NSAIDs may enhance the toxicity of methotrexate. Use caution when NSAIDs are administered concomitantly with methotrexate. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_7"></a><a name="section-7.7"></a><p></p>
<h2>
<span class="Bold">7.</span><span class="Bold">7</span><span class="Bold"> Cyclosporine </span>
</h2>
<p class="First">
		     
	CAMBIA, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Therefore, concomitant therapy with CAMBIA may increase cyclosporine's <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span>. Use caution when CAMBIA is administered concomitantly with cyclosporine. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H7_8"></a><a name="section-7.8"></a><p></p>
<h2>
<span class="Bold">7.8</span><span class="Bold"> Inhibitors of Cytochrome P450 2C9</span>
</h2>
<p class="First">
		     
	Diclofenac is metabolized predominantly by Cytochrome P-450 CYP2C9. Co-administration of  medications that inhibit CYP2C9 may affect the pharmacokinetics of diclofenac <span class="Italics">[see Clinical Pharmacology (</span><a href="#H12_3">12.3</a><span class="Italics">)]</span>.  </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="H8_0"></a><a name="section-8"></a><p></p>
<h1>
<span class="Bold">8</span><span class="Bold"> </span>
		     
	<span class="Bold">USE IN SPECIFIC POPULATIONS</span>
		     
	</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="H8_1"></a><a name="section-8.1"></a><p></p>
<h2>
<span class="Bold">8.1</span><span class="Bold"> Pregnancy </span>
</h2>
<p class="First"><span class="Bold">Pregnancy Category C prior to 30 weeks gestation; Category D starting at 30 weeks gestation.</span></p>
<p>
		     
	Starting at 30 weeks gestation, CAMBIA, and other NSAIDS, should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur <span class="Italics">[see </span><span class="Italics">W</span><span class="Italics">arnings and </span><span class="Italics">P</span><span class="Italics">recautions (</span><span class="Italics"><a href="#H5_9">5.9</a></span><span class="Italics">)]</span>. There are no adequate and well controlled studies in pregnant women. </p>
<p>
		     
	Prior to 30 weeks gestation, CAMBIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
<p>
		     
	Reproductive studies have been performed in mice given diclofenac sodium (up to 20 mg/kg/day, 2 times the recommended human dose [RHD] of 50 mg/day on a body surface area [mg/m<span class="Sup">2</span> basis), and in rats and rabbits given diclofenac sodium (up to 10 mg/kg/day; 2 [rats] and 4 [rabbits] times the RHD on a mg/m<span class="Sup">2</span> basis) and have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> despite the induction of maternal toxicity and fetal toxicity. In rats, maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="H8_2"></a><a name="section-8.2"></a><p></p>
<h2>
<span class="Bold">8.2</span><span class="Bold"> Labor and Delivery</span><span class="Bold"> </span>
</h2>
<p class="First">
		     
	The effects of CAMBIA on labor and delivery in pregnant women are unknown. In rat studies, maternal exposure to NSAIDs, as with other drugs known to inhibit prostaglandin synthesis, increased the incidence of dystocia, delayed parturition, and decreased pup survival.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="H8_3"></a><a name="section-8.3"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">3</span><span class="Bold"> </span><span class="Bold">Nursing Mothers</span>
</h2>
<p class="First">
		     
	It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from CAMBIA, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="H8_4"></a><a name="section-8.4"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">4</span><span class="Bold"> Pediatric Use</span>
</h2>
<p class="First">
		     
	Safety and effectiveness in pediatric patients have not been established. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="H8_5"></a><a name="section-8.5"></a><p></p>
<h2>
<span class="Bold">8.</span><span class="Bold">5</span><span class="Bold"> </span><span class="Bold">Geriatric Use</span>
</h2>
<p class="First">
		     
	Clinical studies of CAMBIA did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
<p>
		     
	Elderly patients are at increased risk for serious GI adverse events.</p>
<p>
		     
	Diclofenac is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken when using CAMBIA in the elderly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H8_6"></a><a name="section-8.6"></a><p></p>
<h2>
<span class="Bold">8.6</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>
</h2>
<p class="First">
		     
	Because hepatic metabolism accounts for almost 100% of diclofenac elimination, patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be considered for treatment with CAMBIA only if the benefits outweigh the risks. There is insufficient information available to support dosing recommendations for CAMBIA in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span>.  <span class="Italics">[see</span><span class="Italics"> </span><span class="Italics">Clinical Pharmacology (</span><a href="#_Hlk216490263">12.3</a><span class="Italics">)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H8_7"></a><a name="section-8.7"></a><p></p>
<h2>
<span class="Bold">8.7 </span><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span>
</h2>
<p class="First">
		     
	No information is available from controlled clinical studies regarding the use of CAMBIA in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. Therefore, treatment with CAMBIA is not recommended in patients with advanced <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.  If CAMBIA therapy must be initiated, close monitoring of the patient's renal function is advisable.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="H10_0"></a><a name="section-9"></a><p></p>
<h1>
<span class="Bold">10</span><span class="Bold"> </span>
		     
	<span class="Bold">OVERDOSAGE</span>
</h1>
<p class="First">
		     
	Symptoms following acute NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> are usually limited to <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, which are generally reversible with supportive care. <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span> can occur. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> may occur, but are rare. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported with therapeutic ingestion of NSAIDs, and may occur following an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. </p>
<p>
		     
	Patients should be managed by symptomatic and supportive care following an NSAID <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. There are no specific antidotes. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> and/or activated charcoal (60 to 100 g in adults, 1 to 2 g/kg in children) and/or osmotic cathartic may be indicated in patients seen within 4 hours of ingestion with symptoms or following a large <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (5 to 10 times the usual dose). Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, alkalinization of urine, hemodialysis, or hemoperfusion may not be useful due to high protein binding.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="H11_0"></a><a name="section-10"></a><p></p>
<h1>
<span class="Bold">11</span><span class="Bold"> </span>
		     
	<span class="Bold">DESCRIPTION</span>
</h1>
<p class="First">
		     
	CAMBIA<span class="Bold"> </span> (Diclofenac Potassium for Oral Solution) is a benzeneacetic acid derivative NSAID. CAMBIA is available as a buffered soluble powder, designed to be mixed with water prior to oral administration.  </p>
<p>
		     
	CAMBIA is a white to off-white, buffered, flavored powder for oral solution packaged in individual unit dose packets <span class="Italics">[see How Supplied/Storage and Handling (</span><span class="Italics"><a href="#H16_0">16</a></span><span class="Italics">)]</span>.  </p>
<p>
		     
	The chemical name for diclofenac potassium is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid monopotassium salt.  The molecular weight of diclofenac potassium is 334.25. Its molecular formula is C<span class="Sub">14</span>H<span class="Sub">10</span>Cl<span class="Sub">2</span>NKO<span class="Sub">2, </span>and it has the following structural formula:</p>
<p>
		     
	      <img alt="Diclofenac Potassium structural formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d7335594-50c9-4ae2-a3e3-b9a375187b62&amp;name=cambia-01.jpg"></p>
<p>
		     
	The inactive ingredients in CAMBIA include: aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glycerol behenate, mannitol, potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, and saccharin sodium.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="H12_0"></a><a name="section-11"></a><p></p>
<h1>
<span class="Bold">12</span><span class="Bold"> </span>
		     
	<span class="Bold">CLINICAL PHARMACOLOGY</span>
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="H12_1"></a><a name="section-11.1"></a><p></p>
<h2>
<span class="Bold">12.1</span><span class="Bold">  Mechanism of Action</span>
</h2>
<p class="First">CAMBIA is a non-steroidal anti-inflammatory drug (NSAID). The mechanism of action of<span class="Bold"> </span>CAMBIA, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition. 
		     
	
		     
	</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="H12_3"></a><a name="section-11.2"></a><p></p>
<h2>
<span class="Bold">12.3</span><span class="Bold">  Pharmacokinetics</span>
</h2>
<p class="First">
		     
	<span class="Underline">Absorption</span>: Diclofenac is 100% absorbed after oral administration compared to intravenous administration as measured by urine recovery. However, due to first-pass metabolism, only about 50% of the absorbed dose is systemically available. In fasting volunteers, measurable plasma levels were observed within 5 minutes of dosing with CAMBIA.  Peak plasma levels were achieved at approximately 0.25 hour in fasting normal volunteers, with a range of 0.17 to 0.67 hours. High fat food had no significant effect on the extent of diclofenac absorption, but there was a reduction in peak plasma levels of approximately 70% after a high fat meal. Decreased Cmax may be associated to decreased effectiveness.</p>
<p>
		     
	<span class="Underline">Distribution</span>: The apparent volume of distribution (V/F) of diclofenac potassium is 1.3 L/kg. </p>
<p>
		     
	Diclofenac is more than 99% bound to human serum proteins, primarily to albumin. Serum protein binding is constant over the concentration range (0.15-105 µg/mL) achieved with recommended doses. </p>
<p>
		     
	<span class="Underline">Metabolism</span>: Five diclofenac metabolites have been identified in human plasma and urine. The metabolites include 4'-hydroxy-, 5-hydroxy-, 3'-hydroxy-, 4',5-dihydroxy- and 3'-hydroxy-4'-methoxy diclofenac. The major diclofenac metabolite, 4’-hydroxydiclofenac, has very weak pharmacologic activity. The formation of 4’-hydroxy diclofenac is primarily mediated by CPY2C9. Both diclofenac and its oxidative metabolites undergo glucuronidation or sulfation followed by biliary excretion. Acylglucuronidation mediated by UGT2B7 and oxidation mediated by CPY2C8 may also play a role in diclofenac metabolism. CYP3A4 is responsible for the formation of minor metabolites, 5-hydroxy and 3’-hydroxy- diclofenac. In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, peak concentrations of metabolites 4'-hydroxy-and 5- hydroxydiclofenac were approximately 50% and 4% of the parent compound after single oral dosing compared to 27% and 1% in normal healthy subjects.</p>
<p>
		     
	<span class="Underline">Excretion</span>: Diclofenac is eliminated through metabolism and subsequent urinary and biliary excretion of the glucuronide and the sulfate conjugates of the metabolites. Little or no free unchanged diclofenac is excreted in the urine. Approximately 65% of the dose is excreted in the urine and approximately 35% in the bile as conjugates of unchanged diclofenac plus metabolites. Because renal elimination is not a significant pathway of elimination for unchanged diclofenac, dosing adjustment in patients with mild to moderate renal dysfunction is not necessary. The terminal half-life of unchanged diclofenac is approximately 2 hours. </p>
<p>
		     
	<span class="Underline">Special Populations</span>: </p>
<p><span class="Italics">Race</span>: There are no pharmacokinetic differences due to race. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span>: The liver metabolizes almost 100% of diclofenac; there is insufficient information available to support dosing recommendations for CAMBIA in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (<a href="#H5_3">5.3</a>, <a href="#H8_6">8.6</a>) </p>
<p><span class="Italics">Renal I</span><span class="Italics">mpairment</span>: In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (inulin clearance 60-90, 30-60, and &lt;30 mL/min; N=6 in each group), AUC values and elimination rate were comparable to those in healthy subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H13_0"></a><a name="section-12"></a><p></p>
<h1>
<span class="Bold">13</span><span class="Bold"> </span>
		     
	<span class="Bold">NON-CLINICAL STUDIES  </span>
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="H13_1"></a><a name="section-12.1"></a><p></p>
<h2>
<span class="Bold">13.1</span><span class="Bold"> Carcinogenesis, Mutagenesis, Impairment of Fertility</span>
</h2>
<p class="First">
		     
	 Long term carcinogenicity studies in rats given diclofenac sodium up to 2 mg/kg/day (less than the recommended human dose [RHD] of 50 mg/day on a body surface area [mg/m<span class="Sup">2</span>] basis) have revealed no significant increases in tumor incidence.  There was a slight increase in benign mammary fibroadenomas in mid-dose treated (0.5 mg/kg/day or 3 mg/m<span class="Sup">2</span>/day ) female rats (high-dose females had excessive mortality), but the increase was not significant for this common rat tumor.  A 2-year carcinogenicity study conducted in mice employing diclofenac sodium at doses up to 0.3 mg/kg/day (less than the RHD on a mg/m<span class="Sup">2</span> basis) in males and 1 m/kg/day (less than the RHD on a mg/m<span class="Sup">2</span> basis) in females did not reveal any oncogenic potential.  </p>
<p>
		     
	Diclofenac sodium was not genotoxic in <span class="Italics">in vitro</span> (reverse mutation in bacteria [Ames], mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> tk) or in <span class="Italics">in vivo</span> (including dominant lethal and male germinal epithelial chromosomal aberration in Chinese hamster) assays.  </p>
<p>
		     
	Diclofenac sodium administered to male and female rats at 4 mg/kg/day (less than the RHD on a mg/m<span class="Sup">2</span> basis) did not affect fertility.</p>
<p>
		     
	</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="T2"></a><a name="section-13"></a><p></p>
<h1>
<span class="Bold">14</span><span class="Bold"> </span>
		     
	<span class="Bold">CLINICAL STUDIES </span>
</h1>
<p class="First">
		     
	The efficacy of CAMBIA in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> was demonstrated in two randomized, double-blind, placebo-controlled trials.</p>
<p>
		     
	Patients enrolled in these two trials were predominantly female (85%) and white (86%), with a mean age of 40 years (range: 18 to 65). Patients were instructed to treat a <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> of moderate to severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with 1 dose of study medication. Patients evaluated their <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> 2 hours later. Associated symptoms of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> were also evaluated. In addition, the proportion of patients who were “sustained <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> free?, defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at 2 hours post-dose without a return of mild, moderate, or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and no use of rescue medication for 24 hours post-dose, was also evaluated. In these studies, the percentage of patients achieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> freedom 2 hours after treatment and sustained <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> freedom from 2 to 24 hours post-dose was significantly greater in patients who received CAMBIA compared with those who received placebo (see <a href="#T2">Table 2</a>).  The percentage of patients achieving <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief 2 hours after treatment (defined as a reduction in <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> severity from moderate or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> to mild or no <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>) was also significantly greater in patients who received CAMBIA compared with those who received placebo (see <a href="#T2">Table 2</a>).</p>
<p>
		     
	</p>
<a name="i03ae26e0-ca5f-4745-890d-457f34f8a33b"></a><table>
<caption><span>Table 2: Percentage of Patients With 2-Hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Freedom, Sustained <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Freedom 2-24 Hours, and 2-Hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief Following Treatment </span></caption>
<col width="202">
<col width="68">
<col width="96">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule">
<span class="Bold">Study 1</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">CAMBIA  (n=265)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Placebo (n=257)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">2-Hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Free</td>
<td class="Lrule Rrule Toprule" align="center">24% </td>
<td class="Lrule Rrule Toprule" align="center">13% </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">2-24h Sustained <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Free </td>
<td class="Lrule Rrule Toprule" align="center">22% </td>
<td class="Lrule Rrule Toprule" align="center">10% </td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">2-Hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief</td>
<td class="Lrule Rrule Toprule" align="center">48% </td>
<td class="Lrule Rrule Toprule" align="center">27% </td>
</tr>
<tr><td class="Lrule Rrule Toprule" colspan="3">                                                                                                       </td></tr>
<tr>
<td class="Lrule Rrule Toprule">
<span class="Bold">Study 2</span><br>
</td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">CAMBIA (n=343)</span></td>
<td class="Lrule Rrule Toprule" align="center"><span class="Bold">Placebo (n=347)</span></td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">2-Hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Free</td>
<td class="Lrule Rrule Toprule" align="center">25%</td>
<td class="Lrule Rrule Toprule" align="center">10%</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule">2-24h Sustained <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Free</td>
<td class="Lrule Rrule Toprule" align="center">19% </td>
<td class="Lrule Rrule Toprule" align="center">7% </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule">2-Hour <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief</td>
<td class="Lrule Rrule Toprule" align="center">65% </td>
<td class="Lrule Rrule Toprule" align="center">41% </td>
</tr>
</tbody>
</table>
<p>
		     
	The estimated probability of achieving <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> freedom within 2 hours following treatment with CAMBIA is shown in Figure 1.</p>
<div class="Figure">
<img alt="Figure 1. Percentage of Patients With Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Freedom Within 2 Hours" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d7335594-50c9-4ae2-a3e3-b9a375187b62&amp;name=cambia-02.jpg"><p class="MultiMediaCaption">Figure 1. Percentage of Patients With Initial <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Freedom Within 2 Hours </p>
</div>
<p>There was a decreased incidence of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span> and <span class="product-label-link" type="condition" conceptid="4209114" conceptname="Phonophobia">phonophobia</span> following administration of CAMBIA, compared to placebo. The efficacy and safety of CAMBIA was unaffected by age or gender of the patient.</p>
<p> </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="H16_0"></a><a name="section-14"></a><p></p>
<h1>
<span class="Bold">16</span><span class="Bold"> </span>
		     
	<span class="Bold">HOW SUPPLIED/STORAGE AND HANDLING</span>
</h1>
<p class="First">
		     
	CAMBIA<span class="Bold">™</span> 50 mg (Diclofenac Potassium for Oral Solution) is supplied as one or more sets of three perforated co-joined individual dose packets. Each individual packet is designed to deliver a dose of 50 mg diclofenac potassium when mixed in water.  </p>
<p>
		     
	CAMBIA is a white to off-white, buffered, flavored powder for oral solution packaged in individual unit dose packets.</p>
<p>Individual CAMBIA<span class="Bold">™</span> Packets - NDC 50192-113-01</p>
<p>Boxes of nine (9) CAMBIA<span class="Bold">™</span> Packets - NDC 50192-113-09</p>
<p>Store at 25°C (77°F) Excursions permitted from 15°C-30°C (59°F-86°F). [See USP Controlled Room Temperature]</p>
<p>Manufactured by: <br>MIPHARM S.p.A.<br>Via Bernardo Quaranta, 12 <br>20141 Milan, Italy</p>
<p>Manufactured for:<br>Nautilus Neurosciences, Inc.<br>135 Rte. 202/206 <br>Bedminster, NJ 08921<br>United States of America</p>
<p>Manufactured and Distributed Under License from APR Applied Pharma Research SA, Balerna Switzerland</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1><span class="Bold">17  PATIENT COUNSELING INFORMATION</span></h1>
<p class="First">
		     
	Inform patients of the availability of a Medication Guide for NSAIDs that accompanies each prescription dispensed, and instruct them to read the  Medication Guide prior to using CAMBIA <span class="Italics">[s</span><span class="Italics">ee Medication Guide (</span><span class="Italics"><a href="#H17_9">17.9</a></span><span class="Italics">)]</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_1"></a><a name="section-15.1"></a><p></p>
<h2>
<span class="Bold">17.1</span><span class="Bold"> Cardiovascular Effects </span>
</h2>
<p class="First">
		     
	CAMBIA, like other NSAIDS, may cause serious CV events, such as MI or<span class="Bold"> </span><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious CV events<span class="Bold"> </span>can occur without warning symptoms, advise patients to be alert for the signs and<span class="Bold"> </span>symptoms of <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, slurring of speech, and to ask<span class="Bold"> </span>for medical advice when observing any indicative sign or symptoms. Inform patients  of the importance of this follow-up <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_1">5.1</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_2"></a><a name="section-15.2"></a><p></p>
<h2>
<span class="Bold">17.</span><span class="Bold">2</span><span class="Bold"> Gastrointestinal Effects</span>
</h2>
<p class="First">
		     
	CAMBIA, like other NSAIDS, can cause GI <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> and more serious GI adverse events such as <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, which may result in hospitalization and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious GI tract ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> can occur without warning symptoms, advise patients to be alert for the signs and symptoms of ulcerations and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and to ask for medical advice when observing any indicative sign or symptoms including <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">epigastric pain</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, and <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Inform patients of the importance of this follow-up <span class="Italics">[see Warnings and Precautions</span><span class="Italics"> </span><span class="Italics">(</span><span class="Italics"><a href="#H5_2">5.2</a></span><span class="Italics">)</span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_3"></a><a name="section-15.3"></a><p></p>
<h2>
<span class="Bold">17.</span><span class="Bold">3</span><span class="Bold"> Hepatotoxicity</span>
</h2>
<p class="First">
		     
	Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, right upper quadrant <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, and “flulike? symptoms). Instruct patients to stop therapy with CAMBIA and seek immediate medical therapy if any of these occur <span class="Italics">[see Warnings and Precautions (</span><a href="#H5_3">5.3</a><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_4"></a><a name="section-15.4"></a><p></p>
<h2>
<span class="Bold">17.4</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span> and <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span>
</h2>
<p class="First">
		     
	Advise patients to promptly report to their physicians signs or symptoms of unexplained <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> during treatment with CAMBIA <span class="Italics">[see Warnings and</span><span class="Italics"> </span><span class="Italics">Precautions (</span><a href="#H5_5">5.5</a><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_5"></a><a name="section-15.5"></a><p></p>
<h2>
<span class="Bold">17.5</span><span class="Bold"> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></span>
</h2>
<p class="First">
		     
	Inform patients of the signs of an <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span> (e.g., <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face or throat). Instruct patients to seek immediate emergency help if these occur <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_7">5.7</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_6"></a><a name="section-15.6"></a><p></p>
<h2>
<span class="Bold">17.</span><span class="Bold">6</span><span class="Bold"> Adverse <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></span>
</h2>
<p class="First">
		     
	CAMBIA, like other NSAIDS, can cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> (SJS), and toxic epidermal <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> (TEN), which may result in hospitalizations and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Although serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> may occur without warning, advise patients to be alert for the signs and symptoms of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, or other signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> such as <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and to ask for medical advice when observing any indicative signs or symptoms. Advise patients to stop CAMBIA immediately if they develop any type of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and to contact their physicians as soon as possible <span class="Italics">[see Warnings and Precautions (</span><span class="Italics"><a href="#H5_8">5.8</a></span><span class="Italics">)]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_7"></a><a name="section-15.7"></a><p></p>
<h2>
<span class="Bold">17.</span><span class="Bold">7</span><span class="Bold"> Effects During Pregnancy</span>
</h2>
<p class="First">
		     
	Starting at 30 weeks gestation, CAMBIA and other NSAIDs should be avoided by pregnant women as premature closure of the ductus arteriosus in the fetus may occur <span class="Italics">[see Use in Specific Populations  (</span><span class="Italics"><a href="#H8_1">8.1</a></span><span class="Italics">)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_8"></a><a name="section-15.8"></a><p></p>
<h2>
<span class="Bold">17.8</span><span class="Bold"> Phenylketonurics</span>
</h2>
<p class="First">
		     
	CAMBIA packets contain aspartame equivalent to phenylalanine 25 mg per packet.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="H17_9"></a><a name="section-15.9"></a><p></p>
<h2>
<span class="Bold">17.9</span><span class="Bold"> </span><span class="Bold">FDA-Approved Medication Guide </span>
</h2>
<p class="First">
		     
	Upon dispensing to a patient please ensure the patient receives the attached Medication Guide.</p>
</div>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-16"></a><p></p>
<h1>MEDGUIDE</h1>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold"> CAMBIA  (Cam-b</span><span class="Bold">ē</span><span class="Bold">-</span><span class="Bold">ə</span><span class="Bold"> or Cam-b</span><span class="Bold">ē</span><span class="Bold">-a)</span> <br><span class="Bold">(diclofe</span><span class="Bold">nac potassium for oral solution)</span></p>
<p>Read the Patient Information that comes with CAMBIA before you start taking it and each time you get a refill.  There may be new information.  This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.  </p>
<p><span class="Bold">What is the most important information I should know about CAMBIA?</span></p>
<p><span class="Bold">CAMBIA, which contains diclofenac, (a non-steroidal anti-inflammatory drug or NSAID), may increase your chance of a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> that can lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This chance is higher:</span></p>
<ul class="Disc">
<li>with longer use of NSAID medicines<br>
</li>
<li>in people who have heart disease</li>
</ul>
<p><span class="Bold">NSAID medicines, such as CAMBIA, should never be used right before or after a heart surgery called a “coronary artery bypass graft? (CABG).</span></p>
<p><span class="Bold">NSAID medicines, such as CAMBIA, can cause <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in your stomach and intestines at any time during treatment. </span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">Ulcers</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>:</span></p>
<ul class="Disc">
<li>can happen without warning symptoms<br>
</li>
<li>may cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></li>
</ul>
<p><span class="Bold">The chance of a person getting an <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increases with:</span></p>
<ul class="Disc">
<li>the use of medicines called steroid hormones (corticosteroids) and blood thinners (anticoagulants)<br>
</li>
<li>longer or regular use <br>
</li>
<li>smoking<br>
</li>
<li>drinking alcohol<br>
</li>
<li>older age<br>
</li>
<li>having poor health</li>
</ul>
<p><span class="Bold">CAMBIA should only be used:</span></p>
<ul class="Disc">
<li>exactly as prescribed<br>
</li>
<li>at the lowest dose possible for your treatment<br>
</li>
<li>for the shortest time needed</li>
</ul>
<p><span class="Bold">What is CAMBIA?</span></p>
<p>CAMBIA is a prescription medicine used to treat <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> attacks in adults.  It does not prevent or lessen the number of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraines</span> you have, and it is not for other types of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>.  CAMBIA contains diclofenac potassium (a Non-Steroidal Anti-Inflammatory Drug or NSAID). </p>
<p><span class="Bold">How should I take CAMBIA? </span></p>
<p>Take CAMBIA exactly as your healthcare provider tells you to take it. </p>
<p>Take 1 dose of CAMBIA to treat your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>:</p>
<ul class="Disc">
<li>remove one single dose packet from a set of three packets <br>
</li>
<li>open packet only when you are ready to use it <br>
</li>
<li>empty contents of packet into 1 to 2 ounces (2 to 4 tablespoons) of water <br>
</li>
<li>mix well and drink the water and powder mixture <br>
</li>
<li>throw away empty packet in a safe place and out of the reach of children <br>
</li>
<li>taking CAMBIA with food may cause a reduction in effectiveness compared to taking CAMBIA on an empty stomach<br>
</li>
<li>do not take more CAMBIA than directed by your healthcare provider. In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, get medical help or contact a Poison Control Center right away</li>
</ul>
<p><span class="Bold">Who should not take CAMBIA?</span></p>
<p>Do not take CAMBIA:</p>
<ul class="Disc">
<li>right before or after heart bypass surgery.  See “What is the most important information I should know about CAMBIA?? <br>
</li>
<li>if you have or have had an <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attack, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, or other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> with aspirin, diclofenac, or any other NSAID medicine</li>
</ul>
<p><span class="Bold">Before you take CAMBIA, tell</span><span class="Bold"> your healthcare provider about </span>all your medical conditions, including if you: </p>
<ul class="Disc">
<li>have a history of <span class="product-label-link" type="condition" conceptid="4265600" conceptname="Gastric ulcer">stomach ulcer</span> or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in your stomach or intestines<br>
</li>
<li>have kidney or liver problems<br>
</li>
<li>have any allergies to any medicines<br>
</li>
<li>have <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, irregular heartbeats<br>
</li>
<li>are pregnant, think you might be pregnant, or are trying to become pregnant. CAMBIA should not be used by pregnant women, especially<span class="Bold"> </span>during the last 3 months of pregnancy unless directed<span class="Bold"> </span>by your healthcare provider to do so. CAMBIA may cause problems in your unborn child or complications during your delivery<br>
</li>
<li>are breastfeeding or plan to breastfeed.  It is not known if CAMBIA passes into your breast milk.  You and your doctor should decide if you will take CAMBIA or breastfeed.  You should not do both  <br>
</li>
<li>have a <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> that is different from your usual <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> </li>
</ul>
<p><span class="Bold">Tell your doctor about all the medicines you take, </span>including prescription and non-prescription medicines, vitamins, and herbal supplements.<span class="Bold">  </span></p>
<p>CAMBIA and other medicines may affect each other, causing side effects.  CAMBIA may affect the way other medicines work, and other medicines may affect how CAMBIA works. </p>
<p><span class="Bold">Especially tell your doctor if you take:</span></p>
<ul class="Disc">
<li>aspirin <br>
</li>
<li>any anticoagulant medicines (warfarin, Coumadin, Jantoven)</li>
</ul>
<p>Know the medicines you take.  Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">What are the possible side effects of CAMBIA?</span></p>
<p><span class="Bold">Serious side effects include:</span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span><br>
</li>
<li>high blood pressure<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> from body <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>)<br>
</li>
<li>kidney problems including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> in the stomach and intestine<br>
</li>
<li>low red blood cells (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>)<br>
</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span><br>
</li>
<li>life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span><br>
</li>
<li>liver problems including life-threatening <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> attacks in people who have <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
</ul>
<p><span class="Bold">Get emergency help right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">heart attack</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>: </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face or throat <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in one part or one side of your body <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">slurred speech</span> </li>
</ul>
<p><span class="Bold">Common side effects include:  </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> 
		     
	<br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></li>
</ul>
<p><span class="Bold">Stop CAMBIA and call your healthcare provider right away if you have any of the following symptoms:  </span></p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> that seems out of proportion to your <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span><br>
</li>
<li><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span> <br>
</li>
<li>sudden or severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in your belly   <br>
</li>
<li>vomit blood<br>
</li>
<li>blood in your bowel movement or it is black and sticky like tar <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blisters</span> with <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4021666" conceptname="Yellow skin">yellow skin</span> or eyes <br>
</li>
<li><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your arms and legs, hands and feet <br>
</li>
<li>unusual <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> <br>
</li>
<li>more tired or weaker than usual <br>
</li>
<li>flu-like symptoms </li>
</ul>
<p>Tell your healthcare provider if you have any side effects that bother you or do not go away. </p>
<p>These are not all the side effects with NSAID medicines. Talk to your healthcare provider or pharmacist for more information about NSAID medicines. </p>
<p>Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store CAMBIA? </span></p>
<ul class="Disc">
<li>store CAMBIA in a dry place at room temperature between 59° to 86°F (15° to 30°C)<br>
</li>
<li>keep CAMBIA and all medicines out of reach of children </li>
</ul>
<p><span class="Bold">General information about CAMBIA </span></p>
<ul class="Disc">
<li>medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use CAMBIA for a condition for which it was not prescribed<br>
</li>
<li>do not give CAMBIA to other people, even if they have the same problem you have. It may harm them<br>
</li>
<li>this Medication Guide contains the most important information about CAMBIA. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider for information written for healthcare professionals<br>
</li>
<li>for more information call Nautilus Neurosciences, Inc at 877-874-2440 (weekdays 9 AM to 5 PM EST) or through our website at www.nautilusneurosciences.com</li>
</ul>
<p> </p>
<p><span class="Bold">What are the ingredients in CAMBIA?</span></p>
<p><span class="Bold">Active ingredients:</span> diclofenac potassium</p>
<p><span class="Bold">Inactive ingredients:</span> aspartame (equivalent to 25 mg phenylalanine), flavoring agents (anise and mint), glyceryl behenate, mannitol, potassium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>, and saccharin sodium</p>
<p>Rx only<br>Issued June 2009<br>Nautilus Neurosciences, Inc.<br>Bedminster, NJ 07921<br>United States of America</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><span class="Bold">CAMBIA</span><span class="Bold"><span class="Sup">TM</span></span><span class="Bold"><br>Diclofenac Potassium for Oral Solution</span><span class="Bold"><br>50 mg</span><span class="Bold"><br>Rx Only</span><span class="Bold"><br>WARNING: Phenylketonurics: Product contains Aspartame, </span><span class="Bold"><br>equivalent to 25 mg phenylalanine</span><span class="Bold"><br>KEEP OUT OF THE REACH OF CHILDREN.</span><span class="Bold"><br>Contains three (3) total packets. </span><br><span class="Bold">NAUTILUS </span><span class="Bold"><br>NEROSCIENCES</span></p>
<p><img alt="PRINCIPAL DISPLAY PANEL
Cambia
Diclofenac Potassium for Oral Solution
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d7335594-50c9-4ae2-a3e3-b9a375187b62&amp;name=cambia-03.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CAMBIA 		
					</strong><br><span class="contentTableReg">diclofenac potassium powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:50192-113</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DICLOFENAC POTASSIUM</strong> (DICLOFENAC) </td>
<td class="formItem">DICLOFENAC POTASSIUM</td>
<td class="formItem">1 mg  in 1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ASPARTAME</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERYL BEHENATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">BICARBONATE</span></strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">    </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">ANISE, MINT</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:50192-113-09</td>
<td class="formItem">09  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">50 mg in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:50192-113-01</td>
<td class="formItem">50 mg in 1 PACKET</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022165</td>
<td class="formItem">04/20/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Nautilus Neurosciences, Inc.
							(832800770)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">MIPHARM SPA</td>
<td class="formItem"></td>
<td class="formItem">514042399</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>3a38ddb1-2e6b-406e-8992-a1c9cbd9acd0</div>
<div>Set id: d7335594-50c9-4ae2-a3e3-b9a375187b62</div>
<div>Version: 4</div>
<div>Effective Time: 20120329</div>
</div>
</div> <div class="DistributorName">Nautilus Neurosciences, Inc.</div></p>
</body></html>
